ClinicalTrials.gg
CompletedNCT01492686Updated Jul 21, 2026Results posted

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

A Phase 3 interventional study of MCI-186 and Placebo in Amyotrophic Lateral Sclerosis (ALS), sponsored by Shionogi. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Shionogi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan — 2 open to participants now, 4 under way, 2 of them phase 3. Amyotrophic Lateral Sclerosis · Japan.

Enrollment
10th of 20
137 · median 136
Started
2011
the only one that year
Phase 3
8 of 21
none open now
Registered
5th of 21
by date
Lead sponsor
3 of 21
Shionogi

Among the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, this one is the 10th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2011, is one of 8 in phase 3, and was the 5th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Amyotrophic Lateral Sclerosis with a site in Japan, or all of them as a file.
02

Study summary

The primary objective of the study is to confirm the efficacy of 60 mg of MCI-186 via intravenous drip infusion once a day in the patients with ALS based on the changes in the revised ALS functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind, placebo-controlled manner. The study is also to examine the safety of MCI-186 to the ALS patients.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis (ALS)
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients whose conditions are defined as "definite ALS"or "probable ALS"diagnostic criteria El Escorial and revised Airlie House.
  • Patients who can eat a meal, excrete, or move with oneself alone, and do not need assistance in everyday life.
  • Patients of less than 2 years after the onset of ALS.
  • Patients whose progress of the condition during 12 weeks before administration meet other requirements.

Exclusion criteria

Exclusion Criteria:

  • Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of to edaravone.
  • Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to .
  • Patients who have participated in other trials within 12 weeks before consent, or who are participating in other clinical trials at present.
  • In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: MCI-186 · Drug: MCI-186 in open label phase

  • Placebo comparator
    Arm 2

    Drug: Placebo · Drug: MCI-186 in open label phase

Interventions

  • Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).

  • DrugPlacebo

    Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).

  • All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks

    0=worst; 48=best

    Time frame: baseline and 24 weeks

Secondary outcomes

  1. Number of Participants With Death or a Specified State of Disease Progression

    Any of "death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech" was defined as an event.

    Time frame: 24 weeks

  2. Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks

    Time frame: baseline and 24 weeks

  3. Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks

    The Modified Norris Scale is a measure of movement disorder for patients with ALS. 0=worst; 102=best

    Time frame: baseline and 24 weeks

  4. Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks

    The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. 200=worst; 40=best

    Time frame: baseline and 24 weeks

  5. Percentage of Participants With Adverse Events

    Time frame: 24 weeks

  6. Percentage of Participants With Adverse Drug Reactions

    Time frame: 24 weeks

  7. Laboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of "Investigations" (PT, MedDRA Ver. 17.0)

    Time frame: 24 weeks

  8. Percentage of Participants With Abnormal Values in Sensory Examinations

    Time frame: baseline and 24 weeks

07

Results

Posted Dec 31, 2018

Participant flow

Double-blind Phase
Participant flow — Double-blind Phase
MilestoneMCI-186Placebo of MCI-186
Started6968
Completed6760
Not completed28
Withdrew: Adverse event02
Withdrew: Physician decision01
Withdrew: Withdrawal by subject02
Withdrew: Due to a discontinuation criterion23
Open-label Phase
Participant flow — Open-label Phase
MilestoneMCI-186Placebo of MCI-186
Started6558
Completed5340
Not completed1218
Withdrew: Adverse event12
Withdrew: Physician decision10
Withdrew: Withdrawal by subject67
Withdrew: Due to a discontinuation criterion49

Outcome measures

PrimaryChange From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks

0=worst; 48=best

Time frame:
baseline and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks
units on a scaleMCI-186Placebo of MCI-186
Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks-5.01 ± 0.64-7.5 ± 0.66
SecondaryNumber of Participants With Death or a Specified State of Disease Progression

Any of "death, disability of independent ambulation, loss of upper limbs function, tracheotomy, use of respirator, use of tube feeding and loss of useful speech" was defined as an event.

Time frame:
24 weeks
Reported as:
Number · Count of Participants
Number of Participants With Death or a Specified State of Disease Progression
Count of ParticipantsMCI-186Placebo of MCI-186
Death00
Disability of independent ambulation02
Loss of upper limbs function00
Tracheotomy10
Use of respirator00
Use of tube feeding01
Loss of useful speech13
SecondaryChange From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
Time frame:
baseline and 24 weeks
Reported as:
Least squares mean · percentage of FVC
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks
percentage of FVCMCI-186Placebo of MCI-186
Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks-15.61 ± 2.41-20.4 ± 2.48
SecondaryChange From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks

The Modified Norris Scale is a measure of movement disorder for patients with ALS. 0=worst; 102=best

Time frame:
baseline and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks
units on a scaleMCI-186Placebo of MCI-186
Change From Baseline in Modified Norris Scale Score in Full Analysis Set (FAS) Population at 24 Weeks-15.91 ± 1.97-20.8 ± 2.06
SecondaryChange From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks

The ALSAQ40 score is a measure of QoL for patients with ALS. The ALSAQ40 evaluates domains that include physical mobility, Activities of daily living (ADL) and independence, eating and drinking, communication, and emotional reactions. 200=worst; 40=best

Time frame:
baseline and 24 weeks
Reported as:
Least squares mean · units on a scale
Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks
units on a scaleMCI-186Placebo of MCI-186
Change From Baseline in ALS Assessment Questionnaire (40 Items) (ALSAQ40) in Full Analysis Set (FAS) Population at 24 Weeks17.25 ± 3.3926.04 ± 3.53
SecondaryPercentage of Participants With Adverse Events
Time frame:
24 weeks
Reported as:
Number · percentage of Participants
Percentage of Participants With Adverse Events
percentage of ParticipantsMCI-186Placebo of MCI-186
Percentage of Participants With Adverse Events84.183.8
SecondaryPercentage of Participants With Adverse Drug Reactions
Time frame:
24 weeks
Reported as:
Number · percentage of Participants
Percentage of Participants With Adverse Drug Reactions
percentage of ParticipantsMCI-186Placebo of MCI-186
Percentage of Participants With Adverse Drug Reactions2.97.4
SecondaryLaboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of "Investigations" (PT, MedDRA Ver. 17.0)
Time frame:
24 weeks
Reported as:
Number · percentage of Participants
Laboratory Tests Percentage of Participants With Adverse Events by System Organ Class (SOC) of "Investigations" (PT, MedDRA Ver. 17.0)
percentage of ParticipantsMCI-186Placebo of MCI-186
Blood bilirubin increased01.5
Blood creatine phosphokinase increased01.5
Liver function test abnormal1.41.5
White blood cell count decreased1.40
SecondaryPercentage of Participants With Abnormal Values in Sensory Examinations
Time frame:
baseline and 24 weeks
Reported as:
Number · percentage of Participants
Percentage of Participants With Abnormal Values in Sensory Examinations
percentage of ParticipantsMCI-186Placebo of MCI-186
Numbness (at baseline)2.97.4
Numbness (at 24 week)7.29.4
Staggering (at baseline)1.48.8
Staggering (at 24 week)2.93.1

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind MCI-186—11/69 (15.9%)57/69 (82.6%)
Double-blind Placebo of MCI-186—16/68 (23.5%)51/68 (75%)
Open-label MCI-186 (Double-blind MCI-186, Then Open-label)—17/65 (26.2%)53/65 (81.5%)
Open-label MCI-186 (Double-blind Placebo, Then Open-label)—23/58 (39.7%)48/58 (82.8%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventDouble-blind MCI-186Double-blind Placebo of MCI-186Open-label MCI-186 (Double-blind MCI-186, Then Open-label)Open-label MCI-186 (Double-blind Placebo, Then Open-label)
DysphagiaGastrointestinal disorders8/698/686/6513/58
Respiratory disorderRespiratory, thoracic and mediastinal disorders2/692/684/654/58
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/692/682/653/58
Respiratory failureRespiratory, thoracic and mediastinal disorders0/690/681/653/58
Musculoskeletal disorderMusculoskeletal and connective tissue disorders0/691/683/652/58
Speech disorderNervous system disorders1/692/682/651/58
Gait disturbanceGeneral disorders0/690/682/650/58
Lower gastrointestinal haemorrhageGastrointestinal disorders0/691/680/651/58
ContusionInjury, poisoning and procedural complications0/691/680/651/58
DepressionPsychiatric disorders0/691/680/651/58
Most frequent other events
Showing 10 of 183
Most frequent other events
EventDouble-blind MCI-186Double-blind Placebo of MCI-186Open-label MCI-186 (Double-blind MCI-186, Then Open-label)Open-label MCI-186 (Double-blind Placebo, Then Open-label)
DysphagiaGastrointestinal disorders0/692/686/6513/58
ContusionInjury, poisoning and procedural complications13/698/686/656/58
ConstipationGastrointestinal disorders8/698/687/658/58
Dermatitis contactSkin and subcutaneous tissue disorders8/693/683/651/58
NasopharyngitisInfections and infestations3/695/686/654/58
EczemaSkin and subcutaneous tissue disorders5/692/685/652/58
PruritusSkin and subcutaneous tissue disorders0/693/685/651/58
HeadacheNervous system disorders4/695/681/653/58
InsomniaPsychiatric disorders5/694/682/652/58
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders5/692/684/651/58

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MCI-186Placebo of MCI-186Total
<=18 years000
Between 18 and 65 years464692
>=65 years232245
Sex: Female, Male
Sex: Female, Male(Participants)MCI-186Placebo of MCI-186Total
Female312758
Male384179
08

Study locations

1 site
  • Osaka, Japan
09

References and documents

Publications

  • Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15. PubMed 28522181 ↗
  • WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP. Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55-63. doi: 10.1080/21678421.2017.1364269. PubMed 28872920 ↗
  • Abrahao A, Da Silva P, Ciepielewska M, Zinman L. Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis. Neurodegener Dis Manag. 2025 Dec;15(6):305-312. doi: 10.1080/17582024.2025.2552610. Epub 2025 Aug 29. PubMed 40878665 ↗
  • Brooks BR, Pioro EP, Sakata T, Takahashi F, Hagan M, Apple S. The effects of intervention with intravenous edaravone in Study 19 on hospitalization, tracheostomy, ventilation, and death in patients with amyotrophic lateral sclerosis. Muscle Nerve. 2023 Oct;68(4):397-403. doi: 10.1002/mus.27946. Epub 2023 Jul 31. PubMed 37525592 ↗
  • Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):49-54. doi: 10.1080/21678421.2017.1361443. PubMed 28872913 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Sep 2014, 32 months.

Results were first posted in Dec 2018, 4 years 3 months after primary completion.

Of 24 phase 3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's 32 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2011
First posted
Dec 15, 2011
StartActual
Dec 31, 2011
Primary completionActual
Sep 30, 2014
CompletionActual
Oct 31, 2014
Results first posted
Dec 31, 2018
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01492686
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Dec 15, 2011
Start date
Dec 31, 2011
Primary completion
Sep 30, 2014
Completion
Oct 31, 2014
Results posted
Dec 31, 2018
Last update
Jul 21, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion